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ORIGINAL RESEARCH

Remote Ischemic Pre-Conditioning
Attenuates Adverse Cardiac Remodeling
and Mortality Following Doxorubicin
Administration in Mice
Zachary M. Gertz, MD,a Chad Cain, BS,a Donatas Kraskauskas, DVM,a Teja Devarakonda, BS,a Adolfo G. Mauro, PHD,a
Jeremy Thompson, BS,a Arun Samidurai, PHD,a Qun Chen, PHD,a Sarah W. Gordon, DO,b Edward J. Lesnefsky, MD,a,b,c
Anindita Das, PHD,a Fadi N. Salloum, PHDa

ABSTRACT
OBJECTIVES Because of its multifaceted cardioprotective effects, remote ischemic pre-conditioning (RIPC) was
examined as a strategy to attenuate doxorubicin (DOX) cardiotoxicity.
BACKGROUND The use of DOX is limited by dose-dependent cardiotoxicity and heart failure. Oxidative stress, mitochondrial dysfunction, inﬂammation, and autophagy modulation have been proposed as mediators of DOX cardiotoxicity.
METHODS After baseline echocardiography, adult male CD1 mice were randomized to either sham or RIPC protocol
(3 cycles of 5 min femoral artery occlusion followed by 5 min reperfusion) 1 h before receiving DOX (20 mg/kg, intraperitoneal). The mice were observed primarily for survival over 85 days (86 mice). An additional cohort of 50 mice was
randomized to either sham or RIPC 1 h before DOX treatment and was followed for 25 days, at which time cardiac ﬁbrosis,
apoptosis, and mitochondrial oxidative phosphorylation were assessed, as well as the expression proﬁles of apoptosis and
autophagy markers.
RESULTS Survival was signiﬁcantly improved in the RIPC cohort compared with the sham cohort (p ¼ 0.007). DOX-induced
cardiac ﬁbrosis and apoptosis were signiﬁcantly attenuated with RIPC compared with sham (p < 0.05 and p < 0.001,
respectively). Although no mitochondrial dysfunction was detected at 25 days, there was a signiﬁcant increase in autophagy
markers with DOX that was attenuated with RIPC. Moreover, DOX caused a 49% decline in cardiac BCL2/BAX expression,
which was restored with RIPC (p < 0.05 vs. DOX). DOX also resulted in a 17% reduction in left ventricular mass at 25 days,
which was prevented with RIPC (p < 0.01), despite the lack of signiﬁcant changes in left ventricular ejection fraction.
CONCLUSIONS Our preclinical results suggested that RIPC before DOX administration might be a promising
approach for attenuating DOX cardiotoxicity. (J Am Coll Cardiol CardioOnc 2019;1:221–34) © 2019 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ABBREVIATIONS
AND ACRONYMS
ADP = adenosine phosphate
DOX = doxorubicin
LV = left ventricular
LVEF = left ventricular ejection
fraction

RIC = remote ischemic
conditioning

RIPC = remote ischemic
pre-conditioning

ROS = reactive oxygen species
STEMI = ST- segment elevation
myocardial infarction

T

he use of doxorubicin (DOX), a
chemotherapeutic

antibiotic

METHODS

from

the anthracycline family, has been

ANIMALS. Adult male CD1 mice were purchased

limited by its dose-dependent cardiotoxicity

from Charles River Laboratories International, Inc.

and related heart failure in cancer survivors

(Wilmington, Massachusetts). The animal experi-

(1,2). Immense research effort has been

mental protocols were approved by the Institutional

focused on attenuating DOX cardiotoxicity

Animal

by modulating its cumulative dose or consid-

Commonwealth University. All animal experiments

ering alternative chemotherapies; however,

were conducted under the guidelines on humane use

DOX remains among the most efﬁcacious

and care of laboratory animals for biomedical

agents for a number of cancers, including

research published by the U.S. National Institutes of

solid

Health (National Institutes of Health Publication No.

and

hematological

malignancies.

Care

and

Use

Committee

of

Virginia

Despite careful adjustment of the cumulative

85-23, revised 1996).

dose, exposure to low or moderate doses of

RIPC AND DOX. Animals were randomized to either

DOX have been associated with early evi-

sham control or RIPC protocol (Figure 1). A subgroup

dence of subclinical cardiovascular disease (3).

of age-matched naive male CD1 mice (n ¼ 12) that did

Studies have indicated the involvement of topoisom-

not receive RIPC or DOX treatment was used as

erase II b inhibition, oxidative stress, mitochondrial

negative control. Under anesthesia (pentobarbital

dysfunction, inﬂammation, and autophagy modula-

30 mg/kg intraperitoneal), all animals had their right

tion, among several other factors, for mediating

femoral artery exposed, and a silk suture was passed

DOX-induced cardiotoxicity and subsequent cardio-

around the artery. For RIPC, the femoral artery was

myopathy (4–8). However, to date, there are no uni-

then occluded by tightening the suture. The artery

versally prescribed or widely used preventive or

was occluded for 5 min, then the suture was relaxed

therapeutic modalities that mitigate DOX cardiotoxic-

for 5 min, then repeated, for a total of 3 cycles of

ity. Recent statistics based on 3 Phase III clinical trials

occlusion and/or reperfusion. The control animals did

estimate that 26% of cancer patients develop cardio-

not have the suture tightened. One hour after RIPC or

toxicity after exposure to a cumulative dose of

control, all animals received a single intraperitoneal

550 mg/m 2 (9), and >50% of all older adult patients
with lymphoma and survivors of childhood cancer
who received DOX treatment remain at high risk of

injection of DOX 20 mg/kg.
All procedures and data analysis were conducted in
a blinded fashion for the various parameters.

developing cardiotoxicity (10).
SURVIVAL. Two cohorts were included in this study:
SEE PAGE 235

1) a long-term cohort that was monitored for survival

Ischemic pre-conditioning refers to sublethal epi-

for 85 days following the experimental procedure

sodes of ischemia that prepare an organ or vascular

(RIPC or sham surgery) and DOX treatment; and 2) a

territory for subsequent prolonged ischemic events

short-term cohort that was killed after 25 days, for

(11,12). Early animal models showed that brief tran-

histological and molecular testing. There were 86

sient occlusions of a coronary artery could dramati-

mice in the long-term cohort, randomized in 1:1

cally limit myocardial infarct size following longer

fashion to RIPC or sham control. The short-term

subsequent ischemia (13). Similar efﬁcacy can be

cohort included 50 mice, similarly randomized. Sur-

attained when the pre-conditioning event occurs in a

vival rate was determined based on the animals that

remote vascular bed, a phenomenon known as

survived the experimental protocol starting at re-

remote ischemic pre-conditioning (RIPC) (14–17). The

covery following RIPC or sham surgery.

mechanism by which RIPC (or any ischemic preconditioning) works is not entirely clear and is
almost certainly multifactorial (18).
The purpose of our study was to determine
whether RIPC can limit DOX-induced cardiotoxicity
in a mouse model. We evaluated the impact of RIPC

ECHOCARDIOGRAPHY. Echocardiography was per-

formed using the Vevo2100 ultrasound system (VisualSonics, Toronto, Ontario, Canada) as previously
reported (19). For methodology details, please refer to
Supplemental Appendix (20,21).

applied in a clinically feasible time of 1 h before DOX

ASSESSMENT OF LV FIBROSIS. Parafﬁn-embedded

administration on survival, cardiac function, left

cardiac tissue sections were stained with picrosirius

ventricular (LV) mass, cardiac ﬁbrosis, apoptosis, and

red to determine interstitial ﬁbrosis as previously

autophagy.

reported (22).
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F I G U R E 1 Animal Randomization Diagram

Consort-style diagram showing animal randomization (1:1) in both sham control (doxorubicin [DOX] alone) and remote ischemic preconditioning (RIPC)þDOX treatment groups. One hour after RIPC or sham control, all animals received a single intraperitoneal injection of
DOX 20 mg/kg. Naive animals did not receive DOX or RIPC. (Top) Chronic cohort (85 days; 86 mice) randomization. (Bottom) Short-term
cohort (25 days; 50 mice) randomization.

APOPTOSIS. Cardiac

cohort (85 days), 4 did not survive the RIPC or sham

apoptosis was detected using the ApoAlert DNA

ASSESSMENT

OF

CARDIAC

procedures and were excluded. The remaining 82

Fragmentation

Mountain

mice (42 RIPC and 40 sham control mice) were

View, California) that detects nuclear DNA fragmen-

included in the long-term survival cohort and

tation. A detailed description can be found in

received DOX 1 h following RIPC or sham procedure.

Assay

Kit

(Clontech,

Supplemental Appendix.

Survival was signiﬁcantly improved in mice subjected

MITOCHONDRIA. Mitochondria were isolated from

to RIPC (p ¼ 0.04) (Figure 2A). Of the initial 50 mice

adult mouse hearts as previously reported (23,24). A

allocated to the short-term study cohort (25 days), 2

detailed

did not survive the RIPC or sham procedures and

description

can

be

found

in

the

Supplemental Appendix.
WESTERN BLOTTING. Cardiac protein extraction was

performed as previously reported (25). Speciﬁc details
can be found in the Supplemental Appendix.
STATISTICAL ANALYSIS. Continuous variables are

presented as mean  SD for normally distributed
variables and median (25th to 75th percentiles) for
non-normal variables. Comparisons were made using

were excluded. The remaining 48 mice (23 RIPC and
25 sham control mice) made up the short-term study
cohort. Similar to the long-term cohort, survival was
signiﬁcantly improved with RIPC compared with DOX
alone at 25 days after treatment (p ¼ 0.035)
(Figure 2B). When the 2 cohorts were combined, the
survival beneﬁt of RIPC was more pronounced
(p ¼ 0.007) (Figure 2C).

a Student’s t-test or Mann-Whitney U test for normal

RIPC

and non-normal variables as appropriate. Survival

MASS. Echocardiographic

rates are presented by Kaplan-Meier plots, which

ducted in both short- and long-term cohorts. Baseline

were compared using the log-rank test. All tests of

left ventricular ejection fraction (LVEF) was similar

signiﬁcance were 2-sided, and p < 0.05 was consid-

between the 2 groups (p ¼ 0.90), did not change at

ered statistically signiﬁcant. Data were analyzed us-

25

ing SPSS version 24 (IBM, Armonk, New York).

(Figure 3A), and remained consistent throughout the

PREVENTS

days

DOX-INDUCED

following

DOX

DECLINE

assessments

treatment

IN

were

(p

LV

con-

¼ 0.83)

study up to 85 days in the long-term cohort. However,

RESULTS

LV mass declined by 17% in the DOX group, which
was completely blunted in the RIPCþDOX mice at

RIPC IMPROVES SURVIVAL AFTER DOX TREATMENT. Of

25 days following DOX treatment (Figure 3B). The

the initial 86 mice allocated to the long-term survival

long-axis view of global longitudinal strain rate
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F I G U R E 2 Survival After DOX in Mice With and Without RIPC

Kaplan-Meier curves show survival in DOX-injected mice with RIPC or sham control. (A) Mice in the long-term survival cohort, (B) mice in the short-term cohort,
and (C) includes both long-term and short-term cohorts. Abbreviations in Figure 1.

analysis did not show any difference between groups

DOX OR RIPCDDOX DID NOT ALTER MITOCHONDRIAL

(Figure 3C). LV dimensions in diastole or systole were

OXIDATIVE PHOSPHORYLATION. The rate of oxidative

not signiﬁcantly different at 25 days (Figures 3D

phosphorylation was determined in mitochondria

and 3E). Cardiac output was signiﬁcantly higher in

isolated from the hearts of mice from the different

RIPCþDOX group compared with the DOX-alone

groups. RIPC before DOX treatment did not alter the

group at 25 days (p ¼ 0.05) (Figure 3F). Additional

protein yield of mitochondria (Table 2). In addition,

cardiac parameter data are presented in Table 1.

there were no differences in the rate of oxidative

RIPC

phosphorylation between the DOX group and the

ATTENUATES

DOX-INDUCED

CARDIAC

FIBROSIS AND APOPTOSIS. DOX treatment resulted

in signiﬁcant cardiac ﬁbrosis 25 days after adminis-

RIPCþDOX group using complex I or complex II substrates. The rates of adenosine phosphate (ADP)

tration, which was attenuated in mice subjected to

stimulated (state 3 respiration), ADP-limited (state 4

RIPC (p < 0.05) (Figure 4). As expected, in age-

respiration), maximal ADP-stimulated state 3 respi-

matched naive mice, there was no remarkable car-

ration (2 mM ADP), and uncoupled respiration (dini-

diac ﬁbrosis.

trophenol stimulated respiration) were all similar.

Terminal deoxynucleotidyl transferase dUTP nick
end labeling staining was used to assess cardiac

These

similar

rates

of

uncoupled

respiration

conﬁrmed that the electron transport chain was un-

apoptosis in the different groups. DOX signiﬁcantly

altered and also excluded a functionally signiﬁcant

increased the frequency of apoptotic nuclei compared

defect

with the naive group, which was mitigated with RIPC

coupling of respiration as shown by the respiratory

(p < 0.001) (Figure 5).

control

in

the

ratio

phosphorylation
was

also

not

apparatus.

affected

by

The
RIPC.
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F I G U R E 3 Echocardiographic Parameters 25 Days Post-DOX Treatment With or Without RIPC

(A) Despite no change in left ventricular (LV) ejection fraction at 25 days following DOX treatment in either group, (B) LV mass signiﬁcantly declined by day 25 following
DOX treatment in the sham group (red) but was preserved with RIPC (blue). (C) Cardiac global strain was not different between groups. No signiﬁcant differences were
reported in LV diameter in (D) diastole and (E) systole. (F) Cardiac output was higher in RIPCþDOX at 25 days. Data presented as mean  SD. Orange ¼ sham baseline;
green ¼ RIPC baseline; red ¼ Sham þ DOX; blue ¼ RIPC þ DOX. AA ¼ anterior apical; AB ¼ anterior basal; AM ¼ anterior mid; PA ¼ posterior anterior; PB ¼ posterior basal;
PM ¼ posterior mid; other abbreviations as in Figure 1.

Mitochondrial respiration in both treatment groups

markers of autophagy, and our data indicated that it

was also similar to that in mitochondria from hearts

was induced by day 25 following DOX treatment
(p < 0.005 vs. control subjects; n ¼ 3) (Figure 7).

of the naive cohort at 25 days following treatment.
RIPC ATTENUATES DOX-INDUCED APOPTOTIC AND
AUTOPHAGIC

SIGNALING. Cardiac

expression

of

BCL2 and BAX, well-known indicators of apoptosis,
was evaluated at 25 days following DOX and RIPC
treatment. The results showed that BCL2 expression
was markedly downregulated in DOX-treated mice
(p < 0.05 vs. control subjects; n ¼ 3) (Figure 6A),
whereas RIPC preserved the expression of BCL2
(p < 0.05 vs. DOX). The expression of pro-apoptotic
protein BAX was induced following DOX treatment,
and it was not blunted by RIPC (p > 0.05 vs. control

Interestingly, RIPC prevented the DOX-induced increase in Beclin expression (p < 0.005 vs. DOX; n ¼ 3).
Moreover, the induction of the ratio of LC-3-II/I also
conﬁrmed the activation of autophagy with DOX
treatment (p < 0.05 vs. control subjects), whereas
RIPC effectively blunted the induction of the LCII/I
ratio (p < 0.05 vs. DOX; n ¼ 3). However, the
expression level of p62, which is expected to be
reciprocally regulated in relation to LC3, was not
altered with DOX or RIPC.

DISCUSSION

subjects; n ¼ 3). Nevertheless, the signiﬁcant 49%
decline in BCL2/BAX ratio illustrated that DOX treat-

Cardiotoxicity secondary to anthracyclines has been

ment enhanced pro-apoptotic signaling and that RIPC

widely documented for the last 5 decades, but the

signiﬁcantly restored the ratio to normal levels.

mechanism

Figure 6B demonstrates a signiﬁcant decline in

Numerous studies have implicated oxidative stress by

phosphorylated AKT1 by day 25 after DOX treatment,

reactive

which was partially preserved with RIPC.

overloadinduced toxicity (26), mitochondrial injury

remains
oxygen

poorly
species

understood
(ROS)

(6),

(10).
iron

We further investigated and analyzed cardiac

further perpetuating cardiac damage (7), and topo-

protein expression of Beclin (BECN1), one of the

isomerase II b inhibition and DNA intercalation (4,5)
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T A B L E 1 Cardiac Physiological Parameters

DOX (n ¼ 18)
Baseline

25 Days

RIPCþDOX (n ¼ 22)
Baseline

p Value

25 Days

25 Days RIPC þ DOX vs. 25 Days DOX

LV mass, mg

115.5  3.9

97.8  4.7

114.6  5.7

105.1  4.6

0.008

LVIDd, mm

4.50  0.01

4.26  0.06

4.38  0.06

4.38  0.09

NS

LVIDs, mm

3.17  0.09

2.68  0.11

3.08  0.08

2.73  0.11

NS

CO, ml/min

21.85  1.12

22.63  1.17

19.26  0.97

25.97  1.43

0.05

N/A

14.61  1.83

N/A

10.60  2.37

<0.001

LV ﬁbrosis, %
Time points for LVEF, %
Baseline

57.4  1.2

55.4  1.3

1 week

61.4  1.7

59.0  3.8

NS

2 weeks

61.2  1.6

62.3  1.6

NS

3 weeks

60.6  1.9

60.7  1.8

NS

5 weeks

57.36  4.9

57.4  3.2

NS

9 weeks

59.7  4.3

55.9  1.7

NS

NS

Segments at LAX longitudinal
strain rate at 3 weeks (Pk%s1)
Posterior base

9.3  2.3

8.5  1.2

NS

Posterior mid

7.2  1.0

5.1  0.5

NS

Posterior apex

7.4  0.8

5.9  0.9

NS

Anterior apex

9.0  0.9

8.6  1.0

NS

Anterior mid

8.3  1.1

5.6  0.5

NS

Anterior base

6.0  0.9

4.4  0.7

NS

Values are mean  SD.
CO ¼ cardiac output; DOX ¼ doxorubicin; LAX ¼ long axis; LV ¼ left ventricle; LVIDd ¼ LV internal diameter diastole; LVIDs ¼ LV internal diameter systole; RIPC ¼ remote
ischemic pre-conditioning.

among many other pathways as mechanisms that

due to cardiac toxicity in cancer survivors still con-

mediate DOX cardiotoxicity. However, therapeutic

tributes to morbidity and mortality in this patient

interventions individually targeting these pathways

population (27). Despite the signiﬁcant improvements

have not yielded much success in alleviating the

in developing new chemotherapeutic drugs as well as

clinical problem. Although limiting the cumulative

small molecule and biological treatment options that

dose of DOX, resorting to liposomal DOX, or use of

have expanded the life span of cancer survivors,

dexrazoxane demonstrated some degree of success in

anthracyclines are still a signiﬁcant portion of the

attenuating cardiac injury, cardiovascular mortality

chemotherapy of choice for several cancers, including

T A B L E 2 Remote Pre-Conditioning Did Not Alter Respiration in Isolated Cardiac Mitochondria at 25 Days

Control Naive (n ¼ 5)

DOX (n ¼ 6)

RIPCþDOX (n ¼ 6)

Complex I substrates: glutamate þ malate
Protein yield (mg/g heart tissue)

27.4 (27.1–28.2)

27.2 (26.3–28.3)

26.2 (25.6–26.6)

443 (438.0–473.0)

507.5 (464.5–537.0)

446.0 (473.3–481.0)

54.0 (47.0–62.0)

62.0 (57.5–65.8)

61.5 (56.5–65.8)

8.0 (7.9–9.4)

8.0 (7.9–8.5)

7.7 (7.2–8.0)

604.0 (576.0–604.0)

596.5 (551.3–602.8)

522.0 (515.0–583.8)

567.0 (532.0–575.0)

574.0 (516.5–603.8)

503.0 (594.0–540.5)

State 3 (ADP stimulated)

894.0 (854.0–923.0)

817.0 (795.3–862.0)

830.0 (787.0–875.3)

State 4 (ADP limited)

222.0 (213.0–240.0)

230.5 (186.5–255.0)

233.5 (218.3–244.3)

3.8 (3.8–3.9)

3.5 (3.3–3.6)

3.4 (3.3–3.6)

2-mM ADP

872.0 (806.0–872.0)

792.5 (729.8–815.5)

784.0 (711.5–846.8)

DNP stimulated

729.0 (715.0–758.0)

678.0 (602.8–720.3)

729.5 (650.5–803.3)

State 3 (ADP stimulated)
State 4 (ADP limited)
RCR
2-mM ADP
DNP stimulated
Complex II substrates: succinate

RCR

Values are median (interquartile range).
ADP ¼ adenosine diphosphate; DNP ¼ dinitrophenol; RCR ¼ respiratory control ratio; other abbreviation as in Table 1.
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F I G U R E 4 Cardiac Fibrosis 25 Days Post-DOX Treatment

Picrosirius red staining of heart sections showed signiﬁcant ﬁbrosis by 25 days following DOX treatment compared with naive control hearts, which was signiﬁcantly
attenuated with RIPC. Data presented as mean  SD. DOX (red circles), RIPCþDOX (blue squares), naive (green triangles). Abbreviations as in Figures 1 and 2.

lymphoma in older adults, childhood cancer, and

that leads to oxidative stress, inﬂammation, mito-

patients with breast cancer (28–31). This information

chondrial dysfunction, and several modalities of cell

motivates investigations into cardioprotective stra-

death (32). This phenomenon was also shown to exert

tegies that are multifaceted to encompass the known

protective effects in other organs in the experimental

and rather unknown aspects and mechanisms of DOX

setting, including the brain, liver, and kidneys. Not

cardiotoxicity (Central Illustration).

only was ischemic pre-conditioning protective when

Myocardial ischemic pre-conditioning was ﬁrst

applied to the same organ that subsequently experi-

described by Murry et al. (11,12) in the mid-1980s and

enced sustained ischemia, but bouts of ischemia and

was inspired by the cardiac warmup phenomenon

reperfusion that affected a vascular bed remote from

that cardiologists had been observing in patients with

the heart, also known as RIPC, were shown to also

a history of angina who subsequently experienced

protect the heart and other organs against sustained

myocardial infarction. The hypothesis behind the

subsequent ischemia (14–17). The mechanism(s) of

initial preclinical studies was that repeated cycles of

action of RIPC seem(s) to involve multiple pathways

short-lived or nonlethal ischemia and reperfusion by

implicated in ischemic pre-conditioning in addition

way of coronary artery occlusion and/or reﬂow would

to

activate protective mechanisms that warn the heart

including exosomes and micro-RNAs (33–35). Mito-

about subsequent prolonged or lethal ischemia,

chondrial

thereby attenuating a host of pathological signaling

perpetuated the production of ROS at the onset of

some

newly
damage

identiﬁed
during

circulating
myocardial

factors,
ischemia
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F I G U R E 5 Cardiac Apoptosis on Day 25 Following DOX Treatment

Terminal deoxynucleotidyl transferase dUTP nick end labeling staining demonstrating signiﬁcant attenuation of cardiac apoptosis in RIPCþDOX group compared with
DOX group, which was signiﬁcantly higher than naive control hearts. Data presented as mean  SD. DOX (red circles), RIPCþDOX (blue squares), naive (green triangles). Arrows indicate apoptotic nuclei. Groups as noted in Figure 1.

F I G U R E 6 Cardiac Proapoptotic and Antiapoptotic Protein Expression and AKT1 Survival Signaling 25 Days Following DOX Treatment

(A) Western blot analysis revealed a signiﬁcant decline in BCL2/BAX ratio with DOX, indicating pro-apoptotic signaling that was blunted with RIPC. (B) Pro-survival
AKT1 phosphorylation was also signiﬁcantly decreased with DOX but was partially preserved with RIPC. Data presented as mean  SD. DOX (red circles), RIPCþDOX
(blue squares), naive (green triangles). Abbreviations as in Figure 1.
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F I G U R E 7 Autophagy Signaling in the Heart 25 Days Post-DOX Administration

Autophagy markers Beclin (BECN1) and LC3-II/I were signiﬁcantly increased by day 25 after DOX treatment, which was abrogated with RIPC. No changes were observed
in p62 expression at this time point. Data presented as mean  SD. DOX (red circles), RIPC þDOX (blue squares), naive (green triangles). Abbreviations as in Figure 1.

reperfusion due to damage incurred in the electron

These changes were also accompanied by attenuation

transport chain (36). Ischemic pre-conditioning, due

of apoptosis, as well as autophagy signaling markers

to upregulation of several antioxidant proteins, was

with RIPC compared with DOX. The persistent in-

effective in attenuating oxidative stress and reducing

crease in autophagy markers by day 25 following DOX

cardiac injury following ischemia (37). Among several

treatment could indicate enduring damage that ne-

observed modalities of cell death in the context of

cessitates removal of impaired components by the

ischemiareperfusion injury and DOX cardiotoxicity,

cell, which was not needed in the RIPC cohort. The

ferroptosis was a key mechanism downstream of

attenuation of cardiac ﬁbrosis and apoptosis indi-

excessive ROS production and iron overload (26).

cated prevention of different modalities of cell death,

ROS-induced oxidation of membrane lipids was

which was suspected to occur over time and ulti-

shown to increase free iron levels—an effect that was

mately led to cardiomyopathy. Because apoptosis is

mitigated

the predominant method of cell death with DOX, our

by

pre-conditioning

before

inducing

ischemia/reperfusion in rats (38).

data, which demonstrated a decline in LV mass with

Because of the similarity of pathological signaling

DOX, were in line with clinical data in the literature

between ischemia/reperfusion injury and DOX car-

and the ability of RIPC to mitigate apoptosis. Its

diotoxicity, the present study evaluated the potential

signaling might explain the preservation of LV mass

protective effect of RIPC against DOX cardiotoxicity

with this treatment (40). Although DOX-induced

in mice (37,39). Our data demonstrated signiﬁcant

mitochondrial dysfunction was implicated in several

reduction in mortality up to 85 days post-DOX

previous studies, our results suggested that RIPC did

administration (p ¼ 0.007), which was associated

not markedly affect mitochondrial function in the

with attenuation of a decrease in LV mass (p ¼ 0.008),

DOX-treated mice, at least at the time point consid-

despite a lack of signiﬁcant changes in LVEF. DOX-

ered in this study, which only took into account mice

induced cardiac ﬁbrosis and apoptosis were also

that survived for 3 weeks after DOX treatment. More

signiﬁcantly mitigated by RIPC (p < 0.05 vs. DOX).

comprehensive assessment of mitochondrial function
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C E NT R AL IL L U STR AT IO N Remote Ischemic Pre-Conditioning Against DOX Cardiotoxicity

Gertz, Z.M. et al. J Am Coll Cardiol CardioOnc. 2019;1(2):221–34.

Key outcomes of improved survival, attenuation of left ventricular (LV) mass decline and mitigation of ﬁbrosis. DOX ¼ doxorubicin.

at earlier time points following DOX treatment is

phosphorylation in the DOX-sham group, which was

warranted.

partially preserved with RIPC. In addition, several

Several studies in the literature evaluated the po-

mechanisms that were shown to mediate DOX

tential beneﬁts of RIPC in clinical settings, which

toxicity in the heart and cardiomyocytes were also

were recently summarized in a meta-analysis of ran-

regulated by RIPC, including micro-RNA-21, soluble

domized trials on remote ischemic conditioning (RIC)

guanylate cyclase activity, protein kinase G, and Sirt3,

during primary percutaneous coronary intervention

among others (43–46).

in patients with ST-segment elevation myocardial

This knowledge led to the design of the ERIC-ONC

infarction (STEMI) (41). The analysis included 8 ran-

(Effect of Remote Ischemic Conditioning in Oncology;

domized trials with 1,083 patients with STEMI who

NCT02471885) trial (47), which is ongoing. This

underwent primary percutaneous coronary interven-

is

tion with RIC and standard of care versus percuta-

controlled study that aims to enroll 128 adult

neous coronary intervention with standard of care

oncology patients who will receive anthracycline-

only. RIC signiﬁcantly reduced infarct size measured

based chemotherapy. The patients will be random-

by biomarker release (p ¼ 0.001), improved ST-

ized in a 1:1 ratio to sham or RIPC with 4 cycles of

a

single-center,

blinded,

randomized,

sham-

segment resolution (p < 0.001), attenuated major

5-min upper arm blood pressure cuff inﬂation and/or

adverse

events

deﬂation immediately before receiving chemotherapy

(p ¼ 0.003), and caused a nonsigniﬁcant decrease in

throughout the treatment regimen. The primary

infarct size assessed by cardiac imaging (p ¼ 0.36).

endpoint will be high-sensitivity troponin T levels

Because most of the evaluated outcomes favored RIC,

over 6 cycles of chemotherapy with follow-up at

the investigators concluded that RIC might improve

12

cardiovascular outcomes in patients with STEMI. In

clinical, electrical (incidence of arrhythmias), struc-

cardiac

and

cerebrovascular

months.

Secondary

endpoints

will

include

addition to the potential beneﬁts of RIPC in the

tural (echocardiography to assess function), and

context of myocardial ischemia, sepsis (35), and cor-

biochemical

onary artery bypass graft surgery (42), preclinical

micro-RNA, and proteomics). This effort is among

studies also indicated that ischemic pre-conditioning

the few nonpharmacological attempts to combat

protected

DOX

cardiomyocytes

against

DOX-induced

parameters

cardiotoxicity.

Other

(mitochondrial

clinical

trials

DNA,

with

toxicity through a mechanism involving PI3K (39).

pharmacotherapy-based approaches to date included

Our data indicated a decrease in cardiac AKT1

the randomized controlled CECCY (Carvedilol Effect
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F I G U R E 8 RIPC Against DOX Cardiotoxicity: Clinical Trial Design

The design of the clinical trial is also included to demonstrate the translational bench-to-bedside efforts at Virginia Commonwealth University. MRI ¼ magnetic
resonance imaging.

231

232

Gertz et al.

JACC: CARDIOONCOLOGY, VOL. 1, NO. 2, 2019
DECEMBER 2019:221–34

RIPC Protects Against DOX Cardiotoxicity

in Preventing Chemotherapy-Induced Cardiotoxicity)

based on the known window of protection offered by

trial, which involved 200 patients and demonstrated

RIPC and the practicality or feasibility of this time

a signiﬁcant reduction in diastolic dysfunction and

point in the clinical setting. However, further studies

troponin I levels over time in breast cancer patients

are needed to reﬁne the time of intervention, because

who were treated with carvedilol while receiving

the efﬁcacy of RIPC was documented starting from

anthracycline chemotherapy (48). The OVERCOME

5 min and lasting up to 72 h (53,54).

(Prevention of the Left Ventricular Dysfunction With

Another limitation was that our study focused on

Enalapril and Carvedilol in Patients Submitted to

male mice that were healthy (i.e., free of cancer and

Intensive Chemotherapy for the Treatment of Malig-

cardiovascular risk factors). This was particularly

nant Hemopathies) trial tested the combination of

important because RIPC failed to reduce myocardial

angiotensin-converting enzyme inhibitors and car-

infarct size in the Zucker fatty rat model of type 2

vedilol in 90 patients. This trial took advantage of

diabetes due to a lack of humoral communication

functional assessment using cardiac magnetic reso-

(55). This might have important implications for

nance in addition to transthoracic echocardiography

cancer patients with type 2 diabetes and warrants

as a primary endpoint (49). The outcomes of this

more in-depth research that also includes female

study indicated that prompt combined treatment

mice, cancer models, and cardiovascular risk factors.

with angiotensin-converting enzyme inhibitors and

Studying the effects of RIPC in a tumor-bearing

ß-blockers might prevent LV systolic dysfunction in

mouse model is also needed to provide in-depth un-

patients with malignant hemopathies who receive

derstanding regarding the effects of RIPC not only on

intensive chemotherapy. In this context, an inter-

the heart, but also on DOX efﬁcacy, if any.

esting study by Cardinale et al. (50) demonstrated
that prompt initiation of treatment played an important role in the extent of LV functional recovery. A
remarkable observation in this study was that most
(98%) cases associated with signiﬁcant decline in LV
function (reduction in LVEF between 10% and 50%)
occurred in the ﬁrst 12 months after DOX treatment,
which highlighted the importance of early detection
and timely intervention for best functional recovery
outcomes. This group also noted that strategies that
targeted prevention of DOX cardiotoxicity would be
preferred, rather than treatment of an established
cardiomyopathy that is progressive and may less
likely

be

reversible

after

surpassing

a

certain

threshold (51). To this end, the application of RIPC
immediately before DOX administration, as was the
case in the present study, might prove more promising than interventions that are applied later in the
course of cardiac dysfunction. Moreover, RIPC is a
noninvasive and safe approach that has been shown
to protect multiple organs, including the heart against
severe ischemia and lung injury after pulmonary
resection in cancer patients (15,52).
STUDY LIMITATIONS. Our study provided proof of

concept that supported the notion of cardioprotection
against DOX toxicity with RIPC. Despite the beneﬁts
reported, there remain some limitations with regard
to the intraperitoneal administration of a single

CONCLUSIONS
The application of RIPC 1 h before DOX administration in adult male mice attenuated mortality, LV mass
decline, cardiac ﬁbrosis, apoptosis, and autophagy
signaling. These ﬁndings suggest that, with further
study, RIPC might prevent or attenuate DOX cardiotoxicity and provide an affordable and noninvasive cardioprotective strategy. The impact of DOX on
cardiac mitochondria should be further addressed
with evaluation of mitochondrial oxidative phosphorylation and overall integrity at earlier time
points in DOX-treated animals. Based on our data and
the ﬁndings reported in the literature, we designed a
single-center clinical trial to test RIPC for prevention
of

anthracycline-related

cardiotoxicity

(Central

Illustration, Figure 8). In terms of patient selection,
chemotherapeutic regimen, and RIPC protocol, our
study design was similar to the ERIC-ONC study (47).
However, although the ERIC-ONC study proposed to
use cardiac troponin change as the primary outcome,
our study uses cardiac magnetic resonance imaging to
evaluate changes in LV function as the primary
outcome (56). Its high reproducibility makes it an
excellent modality for monitoring response to protective interventions against chemotherapy-induced
cardiotoxicity (57), such as that in our proposed trial.

high dose of DOX in our study. Although this
administration route did not resemble the clinical

ADDRESS FOR CORRESPONDENCE: Dr. Fadi N. Sal-

approach, it was consistent with numerous pre-

loum, Virginia Commonwealth University, Division of

clinical studies in mice and rats, and therefore, was

Cardiology, Box 980204, 1101 East Marshall Street, Room

helpful for comparison with other study outcomes.

7-070, Richmond, Virginia 23298. E-mail: fadi.salloum@

We decided to apply RIPC 1 h before DOX injection

vcuhealth.org. Twitter: @SALLOUMFN, @VCUHealth.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The use

ﬁbrosis, apoptosis, and autophagy signaling were

of DOX has been limited by dose-dependent cardiotox-

attenuated.

icity and heart failure. Because of the multifactorial
beneﬁcial signaling pathways elicited by RIPC, we tested

TRANSLATIONAL OUTLOOK: The potential beneﬁt of

the application of RIPC before DOX administration to

RIPC before DOX administration in preventing DOX car-

prevent cardiotoxicity. In adult male mice, survival was

diotoxicity is being tested in human clinical translational

signiﬁcantly improved, and LV mass decline, cardiac

studies, including the ongoing ERIC-ONC trial and our
upcoming clinical trial.
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